Q32 Bio (QTTB) Stock Overview

A clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction. More details

QTTB fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	3/6
Past Performance	3/6
Financial Health	6/6
Dividends	0/6

Rewards

Price-To-Earnings ratio (9.3x) is below the US market (18.2x)

Earnings are forecast to grow 5.41% per year

Became profitable this year

Risk Analysis

Highly volatile share price over the past 3 months compared to the US market

Shareholders have been substantially diluted in the past year

Significant insider selling over the past 3 months

Large one-off items impacting financial results

QTTB Community Fair Values

Create Narrative

See what 7 others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW428,664 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.

Grow your followingReal investors. The kind who actually invest, not scroll past.

Unlock free accessFree premium subscription for consistent and quality authors.

Learn more Create Narrative

428,664 investors already sharing narratives

View all narratives

Q32 Bio Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Q32 Bio
Historical stock prices
Current Share Price	US$10.54
52 Week High	US$23.57
52 Week Low	US$1.78
Beta	-0.38
1 Month Change	-34.00%
3 Month Change	-16.68%
1 Year Change	469.73%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-36.70%

Recent updates

Seeking Alpha • May 28

Q32 Bio: "Buy" On Bempikibart Advancement And Mid-2026 Data Catalysts

Summary I initiate Q32 Bio (QTTB) at 'Buy' due to advancing bempikibart for Alopecia Areata and strong upcoming catalysts. Company expects mid-2026 data from both Part B [36-week topline] and Part A OLE of its phase 2a SIGNAL-AA trial. Recent $55M private placement and prior financings extend cash runway into 1H 2028 and beyond, supporting clinical milestones. Sale of ADX-097 to Akebia secures $12M upfront and potential $592M milestones, while retaining core platform assets. Read the full article on Seeking Alpha

Seeking Alpha • Aug 29

Q32 Bio: High-Risk, High-Reward With Bempikibart And ADX-097

Summary Q32 Bio's Bempikibart and ADX-097 are in Phase 2 trials, targeting autoimmune and inflammatory diseases, with significant potential to address unmet medical needs. The company's unique approach of localized inhibition minimizes side effects and enhances efficacy, differentiating it in the biotech sector. Despite a short cash runway, Q32 Bio's recent merger, strategic reacquisition, and $42 million private placement bolstered its financial position. I rate Q32 Bio as a speculative "Buy" due to the promising drug candidates, but caution about potential dilution and research setbacks. Read the full article on Seeking Alpha

Shareholder Returns

	QTTB	US Biotechs	US Market
7D	-5.0%	0.4%	-0.2%
1Y	469.7%	36.4%	11.9%

Return vs Industry: QTTB exceeded the US Biotechs industry which returned 36.4% over the past year.

Return vs Market: QTTB exceeded the US Market which returned 11.9% over the past year.

Price Volatility

Is QTTB's price volatile compared to industry and market?
QTTB volatility
QTTB Average Weekly Movement	28.2%
Biotechs Industry Average Movement	9.5%
Market Average Movement	6.8%
10% most volatile stocks in US Market	15.0%
10% least volatile stocks in US Market	2.9%

Stable Share Price: QTTB's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: QTTB's weekly volatility (28%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

Founded	Employees	CEO	Website
2017	22	Jodie Morrison	www.q32bio.com

Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human anti–interleukin-7 receptor alpha antagonist monoclonal antibody which completed Phase 2a clinical trials, designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata. It also develops ADX-096, a C3d mAb – CR1 fusion protein for use in ophthalmologic indications, as well as other C3d mAb fusions and nanobodies designed for tissue-targeted complement inhibition and a range of other indications.

Q32 Bio Inc. Fundamentals Summary

How do Q32 Bio's earnings and revenue compare to its market cap?
QTTB fundamental statistics
Market cap	US$313.77m
Earnings (TTM)	US$33.79m
Revenue (TTM)	US$53.74m

9.3x

P/E Ratio

5.8x

P/S Ratio

Is QTTB overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
QTTB income statement (TTM)
Revenue	US$53.74m
Cost of Revenue	US$14.35m
Gross Profit	US$39.39m
Other Expenses	US$5.60m
Earnings	US$33.79m

Last Reported Earnings

Jun 30, 2026

Next Earnings Date

n/a

Earnings per share (EPS)	1.13
Gross Margin	73.30%
Net Profit Margin	62.87%
Debt/Equity Ratio	0%

How did QTTB perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/09/20 01:27
End of Day Share Price	2026/09/18 00:00
Earnings	2026/06/30
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Q32 Bio Inc. is covered by 7 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Imogen Mansfield	Cantor Fitzgerald & Co.
Joseph Pantginis	H.C. Wainwright & Co.
Joseph Catanzaro	Mizuho Securities USA LLC

Q32 Bio (QTTB) Stock Overview

Rewards

Risk Analysis

Join community and earn perks

Q32 Bio Inc. Competitors

Vaxart

MeiraGTx Holdings

Arbutus Biopharma

CapForce

Price History & Performance

Recent News & Updates

Q32 Bio Inc. Announces Executive Appointments

Investor sentiment deteriorates as stock falls 16%

CEO & Director recently sold US$163k worth of stock

Price target decreased by 7.9% to US$41.00

New major risk - Revenue and earnings growth

Q32 Bio Inc. has completed a Follow-on Equity Offering in the amount of $200 million.

Recent updates

Q32 Bio Inc. Announces Executive Appointments

Investor sentiment deteriorates as stock falls 16%

CEO & Director recently sold US$163k worth of stock

Price target decreased by 7.9% to US$41.00

New major risk - Revenue and earnings growth

Q32 Bio Inc. has completed a Follow-on Equity Offering in the amount of $200 million.

Q32 Bio Inc. has filed a Follow-on Equity Offering in the amount of $200 million.

Investor sentiment improves as stock rises 36%

Q32 Bio Inc. has filed a Follow-on Equity Offering in the amount of $200 million.

Price target increased by 63% to US$22.33

Q32 Bio Announces Positive 36-Week Topline Results from Part B of the Signal-Aa Clinical Trial of Bempikibart in Alopecia Areata

Independent Director exercised options to buy US$701k worth of stock.

Q32 Bio Inc. announced that it expects to receive $53.8 million in funding from Atlas Venture Advisors, Inc., OrbiMed Advisors LLC, BVF Partners L.P., RA Capital Management, L.P.

Q32 Bio: "Buy" On Bempikibart Advancement And Mid-2026 Data Catalysts

Investor sentiment improves as stock rises 17%

New major risk - Shareholder dilution

Q32 Bio Inc., Annual General Meeting, Jun 12, 2026

Investor sentiment deteriorates as stock falls 19%

New major risk - Share price stability

Q32 Bio Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

Q32 Bio Inc. has completed a Follow-on Equity Offering in the amount of $14.2 million.

Investor sentiment improves as stock rises 15%

Q32 Bio Inc. has filed a Follow-on Equity Offering in the amount of $14.2 million.

Investor sentiment deteriorates as stock falls 16%

New minor risk - Shareholder dilution

Q32 Bio Inc. has filed a Follow-on Equity Offering in the amount of $10.499996 million.

Mark Iwicki Withdraws Resignation as Chair of the Board and Compensation Committee, as Well as a Member of the Audit Committee of Q32 Bio Inc., Effective December 17, 2025

CEO & Director recently sold US$78k worth of stock

CEO & Director notifies of intention to sell stock

New major risk - Share price stability

Q32 Bio Inc. Sells Complement Inhibitor Adx-097

Q32 Bio Inc. Announces Completion of Enrollment in Part B of Signal-AA Phase 2a Clinical Trial of Bempikibart for Alopecia Areata

New major risk - Share price stability

Q32 Bio Announces Executive Changes

Q32 Bio Receives Written Notice from the Listing Qualifications Staff of the Nasdaq Stock Market

New major risk - Negative shareholders equity

Q32 Bio Inc. Announces FDA Fast Track Designation Granted to Bempikibart (ADX-914) for the Treatment of Alopecia Areata

Q32 Bio Inc. Doses First Patients in Both Part A Open-Label Extension and Part B of Signal-Aa Phase 2A Trial Evaluating Bempikibart in Alopecia Areata

Q32 Bio Inc., Annual General Meeting, Jun 13, 2025

High number of new and inexperienced directors

Q32 Bio Inc. Presents Results from Signal-Aa Part A Clinical Trial Evaluating Bempikibart in Patients with Alopecia Areata At the 2025 American Academy of Dermatology Meeting

Q32 Bio Announces Strategic Restructuring to Focus on Advancement of Bempikibart in Patients with Alopecia Areata

Q32 Bio Provides Bempikibart Program Update, Including Next Steps for Advancing Alopecia Areata Development Program

Q32 Bio Inc. to Present Tissue-Targeted Complement Inhibitor ADX-097 Positive Phase 1 Clinical Trial Results At the American Society of Nephrology Kidney Week 2024

Q32 Bio: High-Risk, High-Reward With Bempikibart And ADX-097

Q32 Bio Announces Completion of Enrollment in the SIGNAL-AD Phase 2 Clinical Trial of Bempikibart for Atopic Dermatitis

Q32 Bio Inc. Provides Corporate Update

High number of new and inexperienced directors

Q32 Bio Inc. Appoints Lee Kalowski as Chief Financial Officer

Q32 Bio Inc. announced that it has received $42 million in funding from a group of investors

No independent directors

Shareholder Returns

Price Volatility

About the Company

Q32 Bio Inc. Fundamentals Summary

Earnings & Revenue

Company Analysis and Financial Data Status

Data Sources

Analysis Model and Snowflake

Industry and Sector Metrics

Analyst Sources